文献速递肺结节与肺癌

可手术非小细胞肺癌的支气管内超声分期:三正常淋巴结是否需要常规活检?

Endobronchial Ultrasound Staging of Operable Non-small Cell Lung Cancer: Do Triple-Normal Lymph Nodes Require Routine Biopsy?
PubMed 文献 · Chest · 2021-01-09

本研究评估cN0非小细胞肺癌患者中,CT、PET和支气管内超声淋巴结评分(CLNS)均正常的三正常淋巴结是否需常规活检。共评估57例患者的143枚淋巴结,三正常淋巴结特异性60%、阴性预测值93.1%,仅5.6%病理证实为恶性。提示三正常淋巴结恶性概率低,可能无需常规采样,但需前瞻性试验确认。

要点

  • 三正常淋巴结定义为CT短径<1 cm、PET无高代谢、EBUS CLNS<2。
  • 三正常淋巴结阴性预测值达93.1%,仅5.6%病理证实为恶性。
  • 结果提示三正常淋巴结或可免于常规EBUS-TBNA采样。

核心结论

  • 联合CT、PET和CLNS可识别三正常淋巴结,其恶性阴性预测值高。
  • 三正常淋巴结是否需常规EBUS-TBNA采样尚需前瞻性试验确认。

研究设计与样本

  • 前瞻性评估cN0非小细胞肺癌患者EBUS下淋巴结超声特征并应用CLNS。
  • 共纳入57例cN0患者,评估143枚淋巴结,以手术切除标本病理为金标准。

主要发现

  • 三正常淋巴结特异性为60%(95%CI,51.2%-68.3%)。
  • 三正常淋巴结阴性预测值为93.1%(95%CI,85.6%-97.4%)。
  • 病理评估后仅5.6%(n=8/143)的三正常淋巴结证实为恶性。

关键数值与推荐

  • 三正常淋巴结定义:CT短轴<1 cm、PET无高代谢活性、EBUS CLNS<2。
  • CLNS<2视为恶性低概率。

临床怎么用

  • 分期时可综合CT、PET和CLNS识别三正常淋巴结,其恶性概率低。
  • 对三正常淋巴结是否省略常规采样需结合临床并等待前瞻性证据。

局限性

  • 研究为单中心小样本(57例患者,143枚淋巴结)。
  • 作者指出需前瞻性试验确认 findings。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Staging guidelines for lung cancer recommend endobronchial ultrasound (EBUS) and systematic biopsy of at least three mediastinal lymph node (LN) stations for accurate staging. A four-point ultrasonographic score (Canada Lymph Node Score [CLNS]) was developed to determine the probability of malignancy in each LN. A LN with a CLNS of < 2 is considered low probability for malignancy. We hypothesized that, in patients with cN0 non-small cell lung cancer, LNs with CLNS of < 2 may not require routine biopsy because they represent true node-negative disease. RESEARCH QUESTION: Do LNs considered triple normal on CT scanning, PET scanning, and CLNS evaluation require routine biopsy? STUDY DESIGN AND METHODS: LNs were evaluated for ultrasonographic features at the time of EBUS and the CLNS was applied. Triple-normal LNs were defined as cN0 on CT scanning (short axis, < 1 cm), PET scanning (no hypermetabolic activity), and EBUS (CLNS, < 2). Specificity and negative predictive value (NPV) were calculated against the gold standard pathologic diagnosis from surgically excised specimens. RESULTS: In total, 143 LNs from 57 cN0 patients were assessed. Triple-normal LNs showed a specificity and NPV of 60% (95% CI, 51.2%-68.3%) and 93.1% (95% CI, 85.6%-97.4%), respectively. After pathologic assessment, only 5.6% (n = 8/143) of triple-normal nodes were proven to be malignant. INTERPRETATION: At the time of staging for lung cancer, combining CT scanning, PET scanning, and CLNS criteria can identify triple-normal LNs that have a high NPV for malignancy. This raises the question of whether triple-normal LNs require routine sampling during EBUS and transbronchial needle aspiration. A prospective trial is required to confirm these findings.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Hylton DA, Kidane B, Spicer J, et al. Endobronchial Ultrasound Staging of Operable Non-small Cell Lung Cancer: Do Triple-Normal Lymph Nodes Require Routine Biopsy? Chest. 2021. PMID: 33434503. doi:10.1016/j.chest.2020.12.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。